SRP+ANB+SURG

PreclinicalSmall molecule

MMedical University of Bialystok

SRP+ANB+SURG is one of 6 small molecule programs targeting Antibiotic Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antibiotic TherapyActive, not recruiting

Antibiotic TherapyPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Antibiotic Therapy

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 2

Rifampicin

Boehringer Ingelheim

Preclinical

1 3

Azithromycin Pill

RRambam Health Care Campus

Preclinical

1 4

Bordetella Pertussis B1917

UUniversity of Southampton

Preclinical

1 5

Antibiotic Withdrawal

CCentre Hospitalier Universitaire, Amiens

Preclinical

1 6

SRP+ANB+SURG

MMedical University of Bialystok

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antibiotic Therapy1 trial

The Influence of Local Antibiotic Therapy on the Outcomes Following Periodontal Regeneration Procedures.

Active, not recruiting·MMedical University of Bialystok·N/A·NCT07027137·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SRP+ANB+SURG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SRP+ANB+SURG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SRP+ANB+SURG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Bialystok company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Bialystok

SRP+ANB+SURG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antibiotic Therapy1 trial

References

Drug Info

Quick Facts

Related News